Ad
related to: best central heating inhibitors for cancer prevention therapy for lung cancer- aNSCLC Patient Support
Find Helpful Resources & Get
Answers About A Treatment Option.
- Patient Support Program
Sign Up For A Patient Support
Program For This aNSCLC Treatment.
- Learn About Treatment
Discover Why This aNSCLC Treatment
Option May Be Right For You.
- About Advanced NSCLC
Find Important Info About Advanced
Non Small Cell Lung Cancer.
- aNSCLC Patient Support
Search results
Results from the WOW.Com Content Network
Topoisomerase II inhibitor. Testicular cancer, ovarian cancer, lung cancer, acute myeloid leukaemia, lymphomas and sarcomas: Myelosuppression, hypersensitivity reactions, Stevens–Johnson syndrome (rare), peripheral neuropathy (uncommon) and secondary malignancies (especially acute myeloid leukaemia). Teniposide: IV: Topoisomerase II inhibitor.
Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases. [1] Sitravatinib is being developed by Mirati Therapeutics. [2] Ongoing phase II trials include a trial for liposarcoma, [3] a combination trial for non-small cell lung cancer, [4] and a combination trial ...
In 2019, the FDA granted accelerated approval to pembrolizumab for people with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. [49] Non-small cell lung cancer (NSCLC) cells expressing programmed death-ligand 1 (PD-L1) could interact with ...
About 2% of all lung cancers are non-carcinoma (mainly sarcoma, tumors of hematopoietic origin, or germ cell tumors. [5] These forms of lung cancer are usually treated differently from carcinomas. Because of the ubiquity of lung carcinomas, however, the term "lung cancer" generally refers to carcinomas in everyday clinical practice. [citation ...
Crizotinib received accelerated approval in 2011 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, while cabozantinib was approved in 2012 for the treatment of medullary thyroid cancer [3] and it has also started clinical trials for the treatment of several other types of cancer.
Use of an inhibitor that blocks the interaction of PD-L1 with the PD-1 receptor can prevent the cancer from evading the immune system in this way. [9] Several PD-1 and PD-L1 inhibitors are being trialled within the clinic for use in advanced melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer and Hodgkin lymphoma, amongst ...
An Hsp90 inhibitor is a substance that inhibits that activity of the Hsp90 heat shock protein. Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of various types of malignancies. [ 2 ]
Hyperthermia therapy (or hyperthermia, or thermotherapy) is a type of medical treatment in which body tissue is exposed to temperatures above body temperature, in the region of 40–45 °C (104–113 °F). Hyperthermia is usually applied as an adjuvant to radiotherapy or chemotherapy, to which it works as a sensitizer, in an effort to treat cancer.
Ad
related to: best central heating inhibitors for cancer prevention therapy for lung cancer